A complete breakdown of teen weight loss medication costs in 2026, including Wegovy pricing, insurance coverage, manufacturer savings programs, and financial assistance options.
If your teenager's pediatrician has recommended weight loss medication, one of the first questions on your mind is likely the cost. Teen weight loss medication cost can be significant — over $1,300 per month at list price for brand-name GLP-1 injections, though insurance coverage and manufacturer savings programs can substantially reduce what you pay. This guide breaks down FDA-approved pediatric weight loss medication options, insurance coverage realities, and ways to reduce your costs.
Here is a snapshot of what FDA-approved teen weight loss medications cost in 2026:
These are medication costs only. A comprehensive treatment program may include additional costs for virtual visits, lab work, and monitoring, which we cover below.
Wegovy is the most well-known GLP-1 medication for teens. It is a once-weekly injection FDA-approved for adolescents ages 12 and older with a BMI at or above the 95th percentile for age and sex (based on CDC growth charts), used as an adjunct to a reduced-calorie diet and increased physical activity. Important: Wegovy is also available as an oral tablet, but only the injectable form is FDA-approved for patients under 18.
The list price for Wegovy is approximately $1,349 per month, or about $16,188 per year. However, very few families pay the full list price. If your insurance covers Wegovy, your out-of-pocket cost depends on your plan's copay and coinsurance structure. With the Wegovy Savings Card from Novo Nordisk, commercially insured patients with existing coverage can save up to $100 per fill, potentially reducing copays to as low as $25 per month (the $25 figure applies when the original copay is $125 or less).
Important: If your insurance does not cover Wegovy at all, the savings card will not help. It only reduces copays for patients who already have insurance coverage for the medication.
Novo Nordisk offers several pricing options:
Note that Novo Nordisk's Patient Assistance Program (PAP) does not currently include Wegovy for weight management. It only covers diabetes medications.
Understanding insurance coverage is critical, as it has the biggest impact on what you actually pay.
According to the KFF 2025 Employer Health Benefits Survey, GLP-1 weight loss coverage varies significantly by employer size — 19% of firms with 200 or more workers and 43% of the largest employers (5,000+ workers) include coverage. Overall, coverage is becoming more restrictive, and the number of people without Wegovy coverage increased 42% year-over-year in 2026.
If your plan does cover these medications, expect to go through a prior authorization process before the prescription is approved.
Medicaid coverage for GLP-1 weight loss medications varies dramatically by state. As of January 2026, only 13 state Medicaid programs cover GLP-1 medications for obesity on a fee-for-service basis. Several states, including California, Pennsylvania, and Michigan, have eliminated or restricted coverage in recent years.
There is no federal mandate requiring Medicaid to cover weight loss medications. However, the CMS BALANCE Model, announced in December 2025, is a voluntary pathway that could expand Medicaid coverage starting as early as May 2026. States can join on a rolling basis from May through December 2026, though participation is voluntary for both states and manufacturers, so expansion is not guaranteed.
The vast majority of insured patients who have GLP-1 coverage must go through prior authorization. In the broader commercial market, over 88% face additional prior authorization requirements according to GoodRx. Here is what the process looks like:
1. Your teen's physician documents their BMI percentile, any related health conditions, and history of prior lifestyle intervention (diet and exercise programs).
2. The physician submits a prior authorization request to your insurer.
3. The insurer reviews the request, typically within 5 to 15 business days.
4. If approved, the medication can be filled at your pharmacy.
5. If denied, you can appeal. First-level appeals involve submitting additional clinical documentation and a letter of medical necessity. Many denials can be overturned on appeal, particularly when supported by strong clinical documentation and a letter of medical necessity.
Common denial reasons include insufficient documentation of prior lifestyle intervention, BMI not meeting the insurer's threshold, age restrictions, and formulary exclusions.
Blueberry Balance is a comprehensive telehealth program that combines medication management with the behavioral and lifestyle support the AAP recommends.
A Blueberry Balance membership includes:
- Virtual consultations with board-certified pediatricians specializing in adolescent obesity
- FDA-approved medication prescribing and ongoing dose management
- Lab work coordination and review
- Growth and development monitoring
- Connected device monitoring between visits
The Blueberry Balance program costs $79 per month. Medication costs are separate from the program fee and depend on which medication is prescribed and your insurance coverage.
Hospital-based pediatric weight management programs are often insurance-based but come with high copays, long wait times (often months), and geographic limitations. Families also face transportation costs and time away from school and work for each visit.
Telehealth programs like Blueberry Balance can offer better value when factoring in the convenience of home-based care, elimination of travel costs, more frequent check-ins, and reduced school absences. In-person specialist visits typically cost $200 to $500 per visit before medication costs.
If cost is a barrier, several options may help:
Your Blueberry Balance pediatrician can help identify the most clinically appropriate medication for your teen's specific situation.
Wegovy's list price is approximately $1,349 per month. With insurance coverage and the Wegovy Savings Card, the copay can be as low as $25 per month. Without insurance coverage, Novo Nordisk offers a self-pay option at $349 per month through NovoCare Pharmacy. Annual costs range from approximately $300 (best-case insured) to $16,188 (full list price).
It depends on your plan. Currently, approximately 19% to 43% of employer plans cover GLP-1 medications for weight loss (varying by employer size, per KFF), and only 13 state Medicaid programs include coverage. Prior authorization is required in nearly all cases. If your initial authorization is denied, appeals are frequently successful with strong clinical documentation.
The total cost includes medication, medical visits, lab work, and monitoring. GLP-1 medications range from $349/month (Wegovy self-pay through NovoCare) to $1,349/month (Wegovy list price). A comprehensive telehealth program adds the cost of virtual visits, coaching, and connected monitoring. Hospital-based programs may cost $200-$500 per specialist visit plus medication.
The most impactful way to reduce costs is through insurance coverage and manufacturer savings programs. With the Wegovy Savings Card, commercially insured patients can pay as little as $25/month. The NovoCare self-pay option brings Wegovy to $349/month without insurance. Your teen's pediatrician can help identify the most cost-effective path based on your coverage.
Blueberry Balance offers comprehensive telehealth-based care that includes medication management, growth and development monitoring, and connected device monitoring — all delivered virtually for $79 per month. When comparing to in-person programs that charge $200-$500 per specialist visit (plus transportation and time away from school), a telehealth program often provides better value and more frequent access to care..
Understanding cost is just the first step. A Blueberry Balance pediatrician can help you find the most affordable, clinically appropriate pediatric weight loss medication for your teen.
Sources:
1. Novo Nordisk NovoCare Wegovy Pricing. novocare.com, 2026.
2. GoodRx. Saxenda Pricing Data, 2026.
3. Kaiser Family Foundation. "Medicaid Coverage of GLP-1 Receptor Agonists." kff.org, 2026.
4. GoodRx. "Tracking Insurance Coverage of Weight Loss Medications," 2026.
5. Centers for Medicare and Medicaid Services. BALANCE Model Announcement, December 2025.
6. Hampl SE, et al. "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity." Pediatrics. 2023;151(2):e2022060640.
This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your child's pediatrician for guidance specific to your teen's health. Pricing information is current as of March 2026 and is subject to change.
.svg)
.svg)
.svg)
